Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.
Eye Research Center, The Five Senses Institute, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.
BMC Ophthalmol. 2024 Jul 29;24(1):316. doi: 10.1186/s12886-024-03588-2.
Stem cell therapy has emerged as a potential therapeutic avenue for optic neuropathy patients. To assess its safety and efficacy, we conducted a systematic review and meta-analysis, focusing on the latest evidence pertaining to the improvement of visual acuity (VA) through stem cell therapy.
We analyzed Each database from its inception until June 2024. PubMed, Scopus, and Google Scholar were systematically searched to identify the included studies. Data were extracted regarding the year of publication, the name of the first author, sample size, VA (Log Mar), and Retinal Nerve Fiber Layer (RNFL) thickness. PRISMA protocol was used as a guide to perform this meta-analysis. STATA 16 was used for statistical analysis.
A total of 66 eyes were examined in seven papers. Based on the meta-analysis, the mean VA (Log MAR) of patients with optic neuropathy improved from 0.90 to 0.65 following stem cell therapy intervention (p-value = 0.001). The thickness of the RNFLs did not demonstrate a significant change (p-value was 0.174).
According to this systematic review and meta-analysis, stem cell therapy may improve the visual acuity of patients with optic neuropathy. Aside from the traditional therapy that can be provided to patients with optic neuropathy, stem cell therapy may also be beneficial.
干细胞疗法已成为治疗视神经病变患者的一种潜在治疗方法。为了评估其安全性和疗效，我们进行了系统评价和荟萃分析，重点关注最新的证据，即通过干细胞疗法改善视力（VA）。
我们分析了每个数据库，从其成立到 2024 年 6 月。通过系统搜索 PubMed、Scopus 和 Google Scholar，以确定包含的研究。提取的数据包括发表年份、第一作者姓名、样本量、VA（对数 MAR）和视网膜神经纤维层（RNFL）厚度。PRISMA 方案被用作指导进行荟萃分析。STATA 16 用于统计分析。
共有 7 篇论文对 66 只眼睛进行了检查。基于荟萃分析，视神经病变患者在接受干细胞治疗干预后，VA（对数 MAR）从 0.90 提高到 0.65（p 值=0.001）。RNFL 厚度没有显著变化（p 值为 0.174）。
根据这项系统评价和荟萃分析，干细胞疗法可能改善视神经病变患者的视力。除了可以为视神经病变患者提供的传统治疗外，干细胞疗法也可能有益。
